

Cover Story
Free
By Matthew Bin Han Ong
The Blue Ribbon Panel—a group of experts selected to identify scientific opportunities for the National Cancer Moonshot Initiative—has submitted 10 recommendations to the National Cancer Advisory Board.
By Laura Brawley
In Brief


Drugs & Targets


Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - Bhattacharya: New grant review criterion is “not political”
- Population-based cancer surveillance is a national treasure at risk
- With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shut down
- Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence